Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook
Alnylam Pharmaceuticals joined the Nasdaq-100 Index on Dec. 22, 2025, as the annual reconstitution took effect before the market opened. Shares traded near $405.60, up 1.3% from the prior close. The company recently announced a $250 million U.S. manufacturing expansion and reported strong adoption of its AMVUTTRA therapy for transthyretin amyloidosis.